Advertisement
Screener

Pacific Biosciences of California, Inc. (PACB) Increase (Decrease) in Contract with Customer, Liability

2.8 / 5 stars · 68/120 Roast Me

Pacific Biosciences of California, Inc. Increase (Decrease) in Contract with Customer, Liability

Pacific Biosciences of California, Inc. (PACB) reported Increase (Decrease) in Contract with Customer, Liability of -$423.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-06

  • Pacific Biosciences of California, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$442.00K.
  • Pacific Biosciences of California, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was $19.00K, a 98.57% decline year-over-year.
  • Pacific Biosciences of California, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$584.00K.
  • Pacific Biosciences of California, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$123.00K.
  • Pacific Biosciences of California, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was $101.00K.
  • Pacific Biosciences of California, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was -$2.11M.
  • Pacific Biosciences of California, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$10.42M.
  • Pacific Biosciences of California, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$3.73M.
Period endIncrease (Decrease) in Contract with Customer, Liability 3 monthIncrease (Decrease) in Contract with Customer, Liability 6 monthIncrease (Decrease) in Contract with Customer, Liability 9 monthIncrease (Decrease) in Contract with Customer, Liability 12 month
2026-06-30-$442.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$423.00K
10-Q · filed 2026-08-06
-$1.01M
derived: sum of 3 quarters · filed 2026-08-06
-$1.13M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$19.00K
10-Q · filed 2026-05-08
-$565.00K
derived: sum of 2 quarters · filed 2026-05-08
-$688.00K
derived: sum of 3 quarters · filed 2026-05-08
-$1.21M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$584.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
-$707.00K
derived: sum of 2 quarters · filed 2026-02-25
-$1.23M
derived: sum of 3 quarters · filed 2026-08-06
$101.00K
10-K · filed 2026-02-25
2025-09-30-$123.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$647.00K
derived: sum of 2 quarters · filed 2026-08-06
$685.00K
10-Q · filed 2025-11-06
-$2.30M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$524.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$808.00K
10-Q · filed 2026-08-06
-$2.17M
derived: sum of 3 quarters · filed 2026-08-06
-$4.35M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$1.33M
10-Q · filed 2026-05-08
-$1.65M
derived: sum of 2 quarters · filed 2026-05-08
-$3.82M
derived: sum of 3 quarters · filed 2026-05-08
-$2.38M
derived: sum of 4 quarters · filed 2026-05-08
2024-12-31-$2.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
-$5.15M
derived: sum of 2 quarters · filed 2026-02-25
-$3.71M
derived: sum of 3 quarters · filed 2026-02-25
-$2.11M
10-K · filed 2026-02-25
2024-09-30-$2.17M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$726.00K
derived: sum of 2 quarters · filed 2025-11-06
$875.00K
10-Q · filed 2025-11-06
-$4.68M
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30$1.45M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$3.05M
10-Q · filed 2025-08-07
-$2.51M
derived: sum of 3 quarters · filed 2026-02-25
-$5.06M
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31$1.60M
10-Q · filed 2025-05-12
-$3.95M
derived: sum of 2 quarters · filed 2026-02-25
-$6.50M
derived: sum of 3 quarters · filed 2026-02-25
-$9.24M
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31-$5.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
-$8.10M
derived: sum of 2 quarters · filed 2026-02-25
-$10.84M
derived: sum of 3 quarters · filed 2026-02-25
-$10.42M
10-K · filed 2026-02-25
2023-09-30-$2.55M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
-$5.29M
derived: sum of 2 quarters · filed 2024-11-12
-$4.87M
10-Q · filed 2024-11-12
-$5.03M
derived: sum of 4 quarters · filed 2025-03-17
2023-06-30-$2.74M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09
-$2.32M
10-Q · filed 2024-08-09
-$2.48M
derived: sum of 3 quarters · filed 2025-03-17
-$3.94M
derived: sum of 4 quarters · filed 2025-03-17
2023-03-31$423.00K
10-Q · filed 2024-05-09
$264.00K
derived: sum of 2 quarters · filed 2025-03-17
-$1.20M
derived: sum of 3 quarters · filed 2025-03-17
-$5.26M
derived: sum of 4 quarters · filed 2025-03-17
2022-12-31-$159.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17
-$1.62M
derived: sum of 2 quarters · filed 2025-03-17
-$5.68M
derived: sum of 3 quarters · filed 2025-03-17
-$3.73M
10-K · filed 2025-03-17
2022-09-30-$1.46M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03
-$5.52M
derived: sum of 2 quarters · filed 2023-11-03
-$3.58M
10-Q · filed 2023-11-03
2022-06-30-$4.06M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04
-$2.12M
10-Q · filed 2023-08-04
2022-03-31$1.95M
10-Q · filed 2023-05-04

Similar stocks

Stock NameCountryMarket CapPE Ratio
908 Devices Inc. (MASS)United States$0.476B-9.53
EyePoint, Inc. (EYPT)United States$0.314B-3.96
Cytek Biosciences, Inc. (CTKB)United States$0.744B-7.15
Quanterix Corp (QTRX)United States$0.150B-1.65
Nautilus Biotechnology, Inc. (NAUT)United States$0.129B-4.16
Seer, Inc. (SEER)United States$0.104B-1.34
Precipio, Inc. (PRPO)United States$0.043B-36.70
HARVARD BIOSCIENCE INC (HBIO)United States$0.037B-2.70
Bionano Genomics, Inc. (BNGO)United States$0.020B-0.42
ASTROTECH Corp (ASTC)United States$0.013B